InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts hold a “Moderate Buy” consensus on InflaRx, with five buy ratings, one strong-buy, two holds, and one sell. The average 12-month price target is $7.43, including recent targets of $6.00 from Cantor Fitzgerald and $8.00 from Needham.
• Institutional ownership increased, with several funds adding or initiating positions; institutional investors and hedge funds now own 42.39% of InflaRx shares.
• InflaRx shares opened at $2.06, while the company’s latest quarterly loss of $0.11 per share missed the $0.07 consensus estimate. Analysts expect a full-year loss of approximately $0.31 per share.

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $7.4286.

Several research analysts recently issued reports on the stock. Cantor Fitzgerald increased their target price on shares of InflaRx from $4.00 to $6.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of InflaRx in a research note on Wednesday, June 24th. Needham & Company LLC assumed coverage on shares of InflaRx in a report on Monday. They set a "buy" rating and a $8.00 price objective on the stock. Finally, Zacks Research cut shares of InflaRx from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 25th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Montanova Capital LLC grew its holdings in shares of InflaRx by 189.1% during the second quarter. Montanova Capital LLC now owns 22,933,910 shares of the company's stock valued at $51,372,000 after buying an additional 15,000,000 shares during the last quarter. Spruce Street Capital LP acquired a new stake in shares of InflaRx in the 2nd quarter worth about $11,988,924. ADAR1 Capital Management LLC bought a new position in InflaRx in the 2nd quarter valued at about $6,720,000. 683 Capital Management LLC boosted its stake in InflaRx by 47.3% during the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company's stock valued at $3,348,000 after purchasing an additional 1,065,000 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in InflaRx during the 2nd quarter valued at about $1,737,000. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Price Performance

Shares of NASDAQ:IFRX opened at $2.06 on Friday. InflaRx has a 1 year low of $0.80 and a 1 year high of $2.95. The business's 50-day moving average is $2.00 and its 200-day moving average is $1.78. The company has a market capitalization of $303.58 million, a price-to-earnings ratio of -3.55 and a beta of 2.52.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Analysts anticipate that InflaRx will post -0.31 EPS for the current year.

InflaRx Company Profile

InflaRx N.V. NASDAQ: IFRX is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company's research centers on the complement system, an important part of the immune response, with particular emphasis on blocking the activity of complement component C5a, which can contribute to excessive inflammation and tissue damage.

InflaRx's lead product candidate is vilobelimab, a monoclonal antibody designed to selectively inhibit C5a while preserving other aspects of the complement system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.